We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Onyx Pharmaceuticals, Inc. (MM) | NASDAQ:ONXX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 124.70 | 0 | 01:00:00 |
From Jul 2019 to Jul 2024
German chemical and pharmaceutical company Bayer AG (BAYN.XE) and Onyx Pharmaceuticals Inc. (ONXX) said Friday they are starting a phase III trial of Nexavar (sorafenib) tablets in patients with non-responsive thyroid cancer.
MAIN FACTS:
-Around 400 thyroid cancer patients with no prior systemic therapy will enroll in a randomized, placebo-controlled study.
-The study's endpoint is progression-free survival, as well as overall survival, time to progression and response rate.
-Nexavar is an oral anti-cancer therapy approved in more than 80 countries for liver cancer, and in more than 90 countries for patients with advanced kidney cancer.
-Frankfurt Bureau, Dow Jones Newswires; 49-69-29725-500
1 Year Onyx Pharmaceuticals, Inc. (MM) Chart |
1 Month Onyx Pharmaceuticals, Inc. (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
